CorMedix Inc Stock News

CorMedix is commercializing DefenCath, the only FDA-approved antimicrobial catheter-lock solution, with strong clinical results and rapid adoption in dialysis clinics. Medicare's TDAPA policy ensures full reimbursement for outpatient treatments, supporting near-term revenue as clinic penetration expands and inpatient rollout begins. Q2 2025 financials show $39.7M net revenue and $19.8M net inco...

CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-marke...

CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The com...

- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.

CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.

CorMedix, Inc. (NASDAQ:CRMD ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Joseph Todisco - CEO & Director Matthew T. David - Executive VP & CFO Conference Call Participants Anish Nikhanj - RBC Capital Markets, Research Division Brandon Richard Folkes - H.C.